Search results for "Late effect"

showing 6 items of 6 documents

Childhood cancer:Survival, treatment modalities, late effects and improvements over time

2021

Since the 1960s, paediatric oncologists have gradually become better organised in large study groups and participation in clinical trials is today considered as the standard of care, with most children with cancer in Europe and North America being enrolled on available treatment protocols. Chemotherapy is nowadays the main element of therapy, but irradiation is still required for some patients. With the advent of multimodality therapy and supportive care, five-year cancer survival exceeds 80 % in most European and North American countries today. The substantial improvements in survival led to a constantly growing population of childhood cancer survivors. Concerns regarding the risk of late …

Cancer Researchmedicine.medical_specialtyTime FactorsSurvivalEpidemiologyPopulationMultimodality TherapySurvivorshipSocial and socioeconomic conditions03 medical and health sciencesSomatic late effects0302 clinical medicineQuality of life (healthcare)NeoplasmsSurvivorship curvemedicineHumans030212 general & internal medicineChild610 Medicine & healthIntensive care medicineeducationSocioeconomic statusClinical Trials as Topiceducation.field_of_studybusiness.industryCancerTemporal changesmedicine.diseaseCombined Modality TherapySurvival AnalysisMental healthSurvivor cohortsEuropeClinical trialTreatment OutcomeOncology030220 oncology & carcinogenesisCancer treatmentNorth AmericaMental late effectsbusinessChildhood cancer360 Social problems & social services
researchProduct

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

2020

PD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first- or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pem…

0301 basic medicineOncologyMelphalanCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPembrolizumablcsh:RC254-282Article03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdverse effectMultiple myelomaPneumonitisbusiness.industryLate effectImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDiscontinuation030104 developmental biologymyelomaOncology030220 oncology & carcinogenesispembrolizumabimmunotherapymedicine.symptombusinessconsolidationmedicine.drug
researchProduct

Evaluación y rehabilitación neuropsicológica en oncología pediátrica.

2003

Objetivo. El presente trabajo tiene como objetivo el estudio de los efectos neuropsicológicos a largo plazo del cáncer infantil y sus tratamientos así como plantear propuestas para la rehabilitación cognitiva. Método. El método ha consistido en una revisión sistemática de los resultados en la literatura científica acerca de los efectos de la quimioterapia y la radioterapia sobre el SNC y en las funciones cognitivas y conductuales detectados a través de estudios de neuroimagen como calcificaciones y cambios en la sustancia blanca. Presentamos, además, el protocolo de evaluación neuropsicológica ejemplificado con un diagnóstico frecuente que presenta deterioro generalizado. Proponemos un prog…

Càncer en els infantslcsh:PsychologyNeuropsychologyCranial irradiationLate effectslcsh:BF1-990RehabilitationPediatric cancer survivorslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282
researchProduct

Managing a Pan-European Consortium on Late Effects among Long-Term Survivors of Childhood and Adolescent Cancer—The PanCareLIFE Project

2021

PanCareLIFE brought together European partners and is the largest study to have evaluated the issues of fertility impairment, hearing loss, and health-related quality of life in survivors of childhood and adolescent cancer. Successful delivery of the project aims did not evolve solely from scientific qualities. Organizational structure and careful information management were key components for its successful completion and are retrospectively assessed in this paper. PanCareLIFE used cohort studies, case-control studies, clinical evaluation of hearing, and genetic testing to study 32,000 survivors from 25 data providers. A management team implemented the organizational structures, was the de…

Information managementAdolescentcancer survivorHealth Toxicology and Mutagenesismedicine.medical_treatmentlcsh:MedicineMedical OncologySupport groupArticle03 medical and health sciences0302 clinical medicineQuality of life (healthcare)BlueprintNeoplasmsHealth caremedicineHumanslate effectsSurvivors030212 general & internal medicineRetrospective Studieshearing lossfertilityMedical educationCancer survivorchildbusiness.industrylcsh:RPublic Health Environmental and Occupational Healthhealth carehealth-related quality of life030220 oncology & carcinogenesisQuality of LifeOrganizational structureepidemiologyBiostatisticsbusinessPsychologyInternational Journal of Environmental Research and Public Health
researchProduct

PanCareLIFE

2018

Aims: Survival after cancer diagnosed during childhood or adolescence continues to improve with new treatments and supportive therapies. Optimal long-term care requires that risks to vulnerable organs are clearly defined and translated into guidelines that are implemented into practice. PanCareLIFE is a pan-European consortium that addresses survivorship issues comprising fertility, hearing impairment and quality of life. This article describes the scientific basis of PanCareLIFE's studies.Methods: PanCareLIFE involves 17 partner institutions from eight European countries, with additional 11 data providers from five other countries. Study designs and methods include molecular genetic, cohor…

MaleGerontologyCancer ResearchLongitudinal studyMedizinPilot ProjectsChildhood cancer survivors0302 clinical medicineNeoplasmsLYMPHOMAMedicineFertility preservationChild610 Medicine & healthEARLY MENOPAUSEOVARIAN-FUNCTIONmedia_commonSURVIVORSOUTCOMES030219 obstetrics & reproductive medicineFertility PreservationGENETIC-VARIATIONCHEMOTHERAPYEuropeOncologyChild Preschool030220 oncology & carcinogenesisCohortFemalemedicine.symptom360 Social problems & social servicesAdultQuality of lifeAdolescentHearing lossmedia_common.quotation_subjectFertilityGuidelinesYoung Adult03 medical and health sciencesQuality of life (healthcare)SDG 3 - Good Health and Well-beingHumansCHILDHOOD-CANCERbusiness.industryClinical study designLate effectsHEARING-LOSSInfant NewbornInfantOtotoxicityLong-Term CareGonadal impairmentLong-term careFeasibility StudiesbusinessFOLLOW-UPEuropean Journal of Cancer
researchProduct

Tin(IV) catalyzed D-galacturonic acid anomerization

2008

A comparative kinetic study of anomerization between the four main forms (alpha/beta-pyranosides and alpha/beta-furanosides) of D-galacturonic acid (GalAH(2), 1) and tin(IV) complexed D-galacturonate ([Sn(CH(3))(2)(GalA)(H(2)O)(2)], 2) in D(2)O, is reported. Important differences are shown by pD vs. mutarotation rate profiles of 1 and 2. Coordination, in fact, causes: i) a spectacular increase of the rate due to kinetic template assistance of the carboxylic tail holding the metal in close proximity to the reactive centre and ii) a change in the dependence of the rate on the pD. Entropic and enthalpic factors contribute to the huge activation energy decrease in 2. Anomerization rates of the …

AnomerMagnetic Resonance SpectroscopyRotationStereochemistrychemistry.chemical_elementMedicinal chemistryMutarotationCatalysisCatalysiskinetic template effectInorganic Chemistrychemistry.chemical_compoundReaction rate constantNMR spectroscopyNucleophilegalacturonic acidanomerizationTin(IV)/ NMR kinetic / Galacturonic / 119SnHexuronic AcidsTin CompoundsStereoisomerismRing sizeKineticschemistryNMR spectroscopy; kinetic template effect; galacturonic acid; Tin(IV) catalysis; anomerizationTinTin(IV) catalysisD-Galacturonic acid
researchProduct